Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
|Articles|April 4, 2022
The Mainstream Patient: April 4
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about the difference between a sun burn and sun poisoning, micro-coring, and more.
Advertisement
In this week’s edition, Self talks sun poisoning and InStyle talks micro-coring. Martha Stewart dives skin aging and Glamour explains why people may be over-sweating. Elle lists the best tinted moisturizers and Allure explores brands using food waste in skin care.
Here’s What ‘Sun Poisoning’ Actually Means, According to Dermatologists
Meet Micro-Coring, the Non-Invasive Anti-Aging Treatment That Gets Rid of Wrinkles and Loose Skin
At What Age Do Most Women Start to See Changes in Their Skin?
Why Do I Sweat in My Sleep? Here’s What the Experts Say—And How to Solve It
20 Tinted Moisturizers That Are Basically The Paris Filter In A Bottle
These Beauty Brands Are Upcycling Food Waste Into New Products
Advertisement
Related to this article
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5